A method of treating lung acute pneumonia

 

(57) Abstract:

The invention relates to medicine, namely to pulmonology, and for the treatment of lung acute pneumonia. To do this, hold the inhalation human leukocyte interferon for 4 doses 2 times a day for 5-8 days, in combination with the introduction of the non-steroidal anti-inflammatory, salt drugs and scarlet. The method allows to increase the efficiency of the recovery process, reduce complications and shorten the treatment time, including due to the failure of antibiotics.

There is a "Method of treatment of persistent viral diseases (Patent N 2020957 Bulletin "Invention" N 19, 1994, S. 44, I. Nesterov Century). The essence of this method of treatment is that leukocyte interferon injected 0.1 - 0.2 ml of 1 times a day, every day in the morning for 2 to 2.5 months and additionally simultaneously orally administered antioxidants and retinoids in the age doses 3 times a day for 2 to 2.5 months, and after 1.5 - 2 months from start of treatment orally administered stimulants production of endogenous interferon plant origin in the age doses 3 times a day for 2 to 2.5 months.

The disadvantage of this method of treatment is the combination with antioxidants, the retinoids and the stimulators of the production of endogenous interferon vegetable origin, as well as intranasal interferon. In acute pneumonia of various etiologies, including viral, it is better inhalation introduction leukocyte interferon for direct effect on bronchial tree and lung tissue.

There are also known methods of inhalation injection of interferon (EN 92014923, EN 1801495).

We have used human leukocyte interferon (CLI) inhalation in patients with mild acute pneumonia.

This group of patients taking non-steroidal anti-inflammatory, salt drugs and scarlet (without antibiotics) conducted inhalation of CLI 4 dose (1 vial), 2 times per day rate from 5 to 8 days.

The total number of patients 10. The average age of 34.5 years. Men 70% women 30%.

The analysis of the treatment results has allowed to establish that radiographically disappeared infiltration and the healing was complete in all observed patients.

The average bed-day was 9.7.

A control group of patients with mild acute pneumonia, the haunted, expectorant drugs, scarlet and physiotherapy, the average bed-day - 14,2.

Thus, the proposed method of use inhalation of CLI in the treatment of patients with mild acute pneumonia eliminates the use of antibiotics and to achieve an earlier recovery.

The technical result of the proposed method is to improve the efficiency of the recovery process, reducing complications and shortening the treatment time due to inhalation of CLI and avoiding antibiotics.

Survey results can be illustrated by the following clinical examples.

Example 1

Patient E., 21, a history N 463, was admitted to the hospital 26.01.96, with complaints of weakness, sweating, headache, cough, fever.

Considers himself ill 4 day. Ill acutely. When contacting the clinic 22.01.96, FG revealed infiltration in the lower lobe of the left lung. Sent to the hospital.

If the inspection is satisfactory, the body temperature of 37.5oskin normal color, frequency of breath - 18 min, percutere dullness over the lower divisions easily., shift leukocyte formula to the left.

In the biochemical analysis of blood increased levels of L1and L2globulins.

In the analysis of sputum leucocytes - 30 - 50 p/SP., the epithelium flat - 0 - 2 p/SP.

Was diagnosed with acute pneumonia, localized in the lower lobe of the left lung, lung during. Bottom.

Treatment: inhalation of CLI 4 doses 2 times a day with 29.01.96, 02.02.96, (5 days), naproxen inside and scarlet intramuscularly.

On day 3 after the start interferonoterapii patient no complaints, auscultatory wheeze not heard.

In FY lungs from 02.02.96, no pathological changes.

Hospital stay was 8 days.

Example 2

Patient B. , 24 years old, history N 1193, was admitted to the hospital 14.03.95, with complaints of weakness, malaise, and cough with bright sputum.

Considers himself ill with 07.03.95, when after a frigorism have a runny nose, increased body temperature up to 38o. Were outpatients about ARD without effect, 09.03.95, health worsened, he had cough with sputum and chest x-ray examination revealed infiltration in the middle lobe of the right lung. Sent to the hospital. what in the dullness of percussion sound right lower angle of the scapula and axillary lines. Over the area of the projection of the average share vyslushala a large amount of wet back of wheezing.

In General, the analysis of blood ESR - 6 mm/h, WBC - 7.0 g/l, shift leukocyte not.

In the biochemical analysis of blood increased levels of L1and L2globulins.

Analysis of sputum produced, little sputum.

Diagnosed with acute right-sided pneumonia with localization in the middle lobe, lung during. Bottom.

Treatment: inhalation of CLI 4 doses 2 times a day with 14.03.95, 22.03.95, (6 days), indomethacin inside and scarlet intramuscularly.

On day 3 of treatment, the patient no complaints, wheezing is not heard.

In FY lungs from 22.03.95, no pathological changes.

Hospital stay was 9 days.

Thus these examples show the effectiveness of inhalation of CLI and the possibility of its use without the use of antibiotics in the treatment of patients with mild acute pneumonia.

A method of treating lung acute pneumonia involving the introduction of human leukocyte interferon the conduct inhalation human leukocyte interferon for 4 doses 2 times a day for 5 8 days.

 

Same patents:
The invention relates to medicine and can be used for the treatment of infectious diseases
The invention relates to medicine, in particular to the treatment of infectious diseases

The invention relates to medicine, namely to methods for treating infectious diseases, including diphtheria

The invention relates to the field of medicine and is intended for treatment of hepatitis
The invention relates to medicine, in particular to Pediatrics, and for the treatment of stenosing laryngotracheitis

The invention relates to medicine, the pharmaceutical industry and applies ointment with human leukocyte interferon

The invention relates to medicine, namely to Oncology, and for the treatment of metastatic liver lesions
The invention relates to pharmacology, specifically to the preparation interferonsource compositions, which can find application in ophthalmology
The invention relates to pharmacology, specifically to the preparation interferonsource compositions, is able to maintain its biological activity, which can be used as drugs for intranasal use, for example, for the preparation of drops in the nose
The invention relates to the medical industry, in particular the production of human leukocyte interferon
The invention relates to medicine, specifically to therapeutic methods for treating tobacco
The invention relates to medicine, specifically to medicines on the basis of herbal remedies designed to treat tobacco
The invention relates to medicine, namely to create homeopathic remedies for erectile dysfunction treatment
The invention relates to medicine and, in particular, to addiction
The invention relates to medicine, cosmetics and food industry

The invention relates to medicine
The invention relates to medicine, namely to cosmetology to remove the tumor epithelial tissues, such as warts

Set alcohol funds // 2146529
The invention relates to medicine, namely to biologically active additives used in addiction, for control and treatment status hangover after acute alcohol intoxication, as well as for prevention and treatment of alcoholism

The invention relates to medicine, namely to pharmacology, to a class of drugs that affect the immune system
Up!